APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Immuno Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oncology Immuno Drug Market Analysis and Forecast 2026-2032

2 January 2026191 pages

Choose your research edition.

Industry ResearchOncology Immuno Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Immuno Drug Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Oncology Immuno Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Immuno Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Immuno Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Oncology Immuno Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Oncology Immuno Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oncology Immuno Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oncology Immuno Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oncology Immuno Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Oncology Immuno Drug include Bristol-Myers Squibb, Dendreon Pharmaceuticals, Gilead Sciences Inc., Merck & Co, Sanofi S.A., AstraZeneca, Roche AG, Merck KGaA and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Oncology Immuno Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oncology Immuno Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Oncology Immuno Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oncology Immuno Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oncology Immuno Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Oncology Immuno Drug sales, projected growth trends, production technology, application and end-user industry.

Oncology Immuno Drug Segment by Company

Bristol-Myers Squibb

Dendreon Pharmaceuticals

Gilead Sciences Inc.

Merck & Co

Sanofi S.A.

AstraZeneca

Roche AG

Merck KGaA

Novartis

Oncology Immuno Drug Segment by Type

CAR-T Cell Therapy

Cancer Vaccines

Cytokine-Based Immunotherapy

Immune Checkpoint Inhibitors

Other

Oncology Immuno Drug Segment by Application

Hospitals

Drugstores

Others

Oncology Immuno Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Immuno Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Immuno Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Immuno Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Oncology Immuno Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Immuno Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oncology Immuno Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CAR-T Cell Therapy Major Manufacturers Table 3. Cancer Vaccines Major Manufacturers Table 4. Cytokine-Based Immunotherapy Major Manufacturers Table 5. Immune Checkpoint Inhibitors Major Manufacturers Table 6. Other Major Manufacturers Table 7. Global Oncology Immuno Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Manufacturers Table 9. Drugstores Major Manufacturers Table 10. Others Major Manufacturers Table 11. Oncology Immuno Drug Industry Trends Table 12. Oncology Immuno Drug Industry Drivers Table 13. Oncology Immuno Drug Industry Opportunities and Challenges Table 14. Oncology Immuno Drug Industry Restraints Table 15. Global Oncology Immuno Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Oncology Immuno Drug Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Oncology Immuno Drug Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Oncology Immuno Drug Revenue Market Share by Region (2021-2026) Table 19. Global Oncology Immuno Drug Revenue Market Share by Region (2027-2032) Table 20. Global Oncology Immuno Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Oncology Immuno Drug Sales by Region (2021-2026) & (K Units) Table 22. Global Oncology Immuno Drug Sales by Region (2027-2032) & (K Units) Table 23. Global Oncology Immuno Drug Sales Market Share by Region (2021-2026) Table 24. Global Oncology Immuno Drug Sales Market Share by Region (2027-2032) Table 25. Global Oncology Immuno Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Oncology Immuno Drug Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Oncology Immuno Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Oncology Immuno Drug Sales Market Share by Manufacturers (2021-2026) Table 29. Global Oncology Immuno Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Oncology Immuno Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Oncology Immuno Drug Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Oncology Immuno Drug Manufacturers, Product Type & Application Table 33. Global Oncology Immuno Drug Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Oncology Immuno Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Oncology Immuno Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Oncology Immuno Drug Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Oncology Immuno Drug Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Oncology Immuno Drug Revenue Market Share by Type (2021-2026) Table 40. Global Oncology Immuno Drug Revenue Market Share by Type (2027-2032) Table 41. Global Oncology Immuno Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 43. Global Oncology Immuno Drug Sales by Type (2027-2032) & (K Units) Table 44. Global Oncology Immuno Drug Sales Market Share by Type (2021-2026) Table 45. Global Oncology Immuno Drug Sales Market Share by Type (2027-2032) Table 46. Global Oncology Immuno Drug Price by Type (2021-2026) & (US$/Unit) Table 47. Global Oncology Immuno Drug Price by Type (2027-2032) & (US$/Unit) Table 48. Global Oncology Immuno Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Oncology Immuno Drug Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Oncology Immuno Drug Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Oncology Immuno Drug Revenue Market Share by Application (2021-2026) Table 52. Global Oncology Immuno Drug Revenue Market Share by Application (2027-2032) Table 53. Global Oncology Immuno Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Oncology Immuno Drug Sales by Application (2027-2032) & (K Units) Table 56. Global Oncology Immuno Drug Sales Market Share by Application (2021-2026) Table 57. Global Oncology Immuno Drug Sales Market Share by Application (2027-2032) Table 58. Global Oncology Immuno Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Oncology Immuno Drug Price by Application (2027-2032) & (US$/Unit) Table 60. Bristol-Myers Squibb Company Information Table 61. Bristol-Myers Squibb Business Overview Table 62. Bristol-Myers Squibb Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio Table 64. Bristol-Myers Squibb Recent Development Table 65. Dendreon Pharmaceuticals Company Information Table 66. Dendreon Pharmaceuticals Business Overview Table 67. Dendreon Pharmaceuticals Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio Table 69. Dendreon Pharmaceuticals Recent Development Table 70. Gilead Sciences Inc. Company Information Table 71. Gilead Sciences Inc. Business Overview Table 72. Gilead Sciences Inc. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio Table 74. Gilead Sciences Inc. Recent Development Table 75. Merck & Co Company Information Table 76. Merck & Co Business Overview Table 77. Merck & Co Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Merck & Co Oncology Immuno Drug Product Portfolio Table 79. Merck & Co Recent Development Table 80. Sanofi S.A. Company Information Table 81. Sanofi S.A. Business Overview Table 82. Sanofi S.A. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Sanofi S.A. Oncology Immuno Drug Product Portfolio Table 84. Sanofi S.A. Recent Development Table 85. AstraZeneca Company Information Table 86. AstraZeneca Business Overview Table 87. AstraZeneca Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. AstraZeneca Oncology Immuno Drug Product Portfolio Table 89. AstraZeneca Recent Development Table 90. Roche AG Company Information Table 91. Roche AG Business Overview Table 92. Roche AG Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Roche AG Oncology Immuno Drug Product Portfolio Table 94. Roche AG Recent Development Table 95. Merck KGaA Company Information Table 96. Merck KGaA Business Overview Table 97. Merck KGaA Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Merck KGaA Oncology Immuno Drug Product Portfolio Table 99. Merck KGaA Recent Development Table 100. Novartis Company Information Table 101. Novartis Business Overview Table 102. Novartis Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Novartis Oncology Immuno Drug Product Portfolio Table 104. Novartis Recent Development Table 105. North America Oncology Immuno Drug Revenue by Type (2021-2026) & (US$ Million) Table 106. North America Oncology Immuno Drug Revenue by Type (2027-2032) & (US$ Million) Table 107. North America Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 108. North America Oncology Immuno Drug Sales by Type (2027-2032) & (K Units) Table 109. North America Oncology Immuno Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 110. North America Oncology Immuno Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 111. North America Oncology Immuno Drug Revenue by Application (2021-2026) & (US$ Million) Table 112. North America Oncology Immuno Drug Revenue by Application (2027-2032) & (US$ Million) Table 113. North America Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 114. North America Oncology Immuno Drug Sales by Application (2027-2032) & (K Units) Table 115. North America Oncology Immuno Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 116. North America Oncology Immuno Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 117. North America Oncology Immuno Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. North America Oncology Immuno Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 119. North America Oncology Immuno Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 120. North America Oncology Immuno Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 121. North America Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 122. North America Oncology Immuno Drug Sales by Country (2027-2032) & (K Units) Table 123. North America Oncology Immuno Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 124. North America Oncology Immuno Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 125. United States Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 126. Canada Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 127. Europe Oncology Immuno Drug Revenue by Type (2021-2026) & (US$ Million) Table 128. Europe Oncology Immuno Drug Revenue by Type (2027-2032) & (US$ Million) Table 129. Europe Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 130. Europe Oncology Immuno Drug Sales by Type (2027-2032) & (K Units) Table 131. Europe Oncology Immuno Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 132. Europe Oncology Immuno Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 133. Europe Oncology Immuno Drug Revenue by Application (2021-2026) & (US$ Million) Table 134. Europe Oncology Immuno Drug Revenue by Application (2027-2032) & (US$ Million) Table 135. Europe Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 136. Europe Oncology Immuno Drug Sales by Application (2027-2032) & (K Units) Table 137. Europe Oncology Immuno Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 138. Europe Oncology Immuno Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 139. Europe Oncology Immuno Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Europe Oncology Immuno Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. Europe Oncology Immuno Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. Europe Oncology Immuno Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 143. Europe Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 144. Europe Oncology Immuno Drug Sales by Country (2027-2032) & (K Units) Table 145. Europe Oncology Immuno Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 146. Europe Oncology Immuno Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 147. Germany Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 148. France Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 149. U.K. Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 150. Italy Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 151. Netherlands Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 152. Nordic Countries Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 153. China Oncology Immuno Drug Revenue by Type (2021-2026) & (US$ Million) Table 154. China Oncology Immuno Drug Revenue by Type (2027-2032) & (US$ Million) Table 155. China Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 156. China Oncology Immuno Drug Sales by Type (2027-2032) & (K Units) Table 157. China Oncology Immuno Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 158. China Oncology Immuno Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 159. China Oncology Immuno Drug Revenue by Application (2021-2026) & (US$ Million) Table 160. China Oncology Immuno Drug Revenue by Application (2027-2032) & (US$ Million) Table 161. China Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 162. China Oncology Immuno Drug Sales by Application (2027-2032) & (K Units) Table 163. China Oncology Immuno Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 164. China Oncology Immuno Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 165. Asia Oncology Immuno Drug Revenue by Type (2021-2026) & (US$ Million) Table 166. Asia Oncology Immuno Drug Revenue by Type (2027-2032) & (US$ Million) Table 167. Asia Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 168. Asia Oncology Immuno Drug Sales by Type (2027-2032) & (K Units) Table 169. Asia Oncology Immuno Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 170. Asia Oncology Immuno Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 171. Asia Oncology Immuno Drug Revenue by Application (2021-2026) & (US$ Million) Table 172. Asia Oncology Immuno Drug Revenue by Application (2027-2032) & (US$ Million) Table 173. Asia Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 174. Asia Oncology Immuno Drug Sales by Application (2027-2032) & (K Units) Table 175. Asia Oncology Immuno Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 176. Asia Oncology Immuno Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 177. Asia Oncology Immuno Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 178. Asia Oncology Immuno Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 179. Asia Oncology Immuno Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 180. Asia Oncology Immuno Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 181. Asia Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 182. Asia Oncology Immuno Drug Sales by Country (2027-2032) & (K Units) Table 183. Asia Oncology Immuno Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 184. Asia Oncology Immuno Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 185. Japan Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 186. South Korea Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 187. India Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 188. Australia Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 189. China Taiwan Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 190. Southeast Asia Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 191. SAMEA Oncology Immuno Drug Revenue by Type (2021-2026) & (US$ Million) Table 192. SAMEA Oncology Immuno Drug Revenue by Type (2027-2032) & (US$ Million) Table 193. SAMEA Oncology Immuno Drug Sales by Type (2021-2026) & (K Units) Table 194. SAMEA Oncology Immuno Drug Sales by Type (2027-2032) & (K Units) Table 195. SAMEA Oncology Immuno Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 196. SAMEA Oncology Immuno Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 197. SAMEA Oncology Immuno Drug Revenue by Application (2021-2026) & (US$ Million) Table 198. SAMEA Oncology Immuno Drug Revenue by Application (2027-2032) & (US$ Million) Table 199. SAMEA Oncology Immuno Drug Sales by Application (2021-2026) & (K Units) Table 200. SAMEA Oncology Immuno Drug Sales by Application (2027-2032) & (K Units) Table 201. SAMEA Oncology Immuno Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 202. SAMEA Oncology Immuno Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 203. SAMEA Oncology Immuno Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 204. SAMEA Oncology Immuno Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 205. SAMEA Oncology Immuno Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 206. SAMEA Oncology Immuno Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 207. SAMEA Oncology Immuno Drug Sales by Country (2021-2026) & (K Units) Table 208. SAMEA Oncology Immuno Drug Sales by Country (2027-2032) & (K Units) Table 209. SAMEA Oncology Immuno Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 210. SAMEA Oncology Immuno Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 211. Brazil Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 212. Argentina Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 213. Chile Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 214. Colombia Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 215. Peru Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 216. Saudi Arabia Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 217. Israel Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 218. UAE Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 219. Turkey Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 220. Iran Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 221. Egypt Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. Oncology Immuno Drug Distributors List Table 225. Oncology Immuno Drug Customers List Table 226. Research Programs/Design for This Report Table 227. Authors List of This Report Table 228. Secondary Sources Table 229. Primary Sources List of Figures Figure 1. Oncology Immuno Drug Image Figure 2. Global Oncology Immuno Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Immuno Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. CAR-T Cell Therapy Image Figure 5. Cancer Vaccines Image Figure 6. Cytokine-Based Immunotherapy Image Figure 7. Immune Checkpoint Inhibitors Image Figure 8. Other Image Figure 9. Global Oncology Immuno Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Oncology Immuno Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Drugstores Image Figure 13. Others Image Figure 14. Global Oncology Immuno Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Oncology Immuno Drug Revenue (2021-2032) & (US$ Million) Figure 16. Global Oncology Immuno Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Oncology Immuno Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Oncology Immuno Drug Revenue Market Share by Region (2021-2032) Figure 19. Global Oncology Immuno Drug Sales (2021-2032) & (K Units) Figure 20. Global Oncology Immuno Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Oncology Immuno Drug Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Oncology Immuno Drug Sales YoY (2021-2032) & (K Units) Figure 23. Europe Oncology Immuno Drug Sales YoY (2021-2032) & (K Units) Figure 24. China Oncology Immuno Drug Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Oncology Immuno Drug Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Oncology Immuno Drug Sales YoY (2021-2032) & (K Units) Figure 27. Global Oncology Immuno Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Oncology Immuno Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Oncology Immuno Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Oncology Immuno Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Oncology Immuno Drug Revenue Market Share by Type (2021-2032) Figure 33. Global Oncology Immuno Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Oncology Immuno Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Oncology Immuno Drug Sales Market Share by Type (2021-2032) Figure 36. Global Oncology Immuno Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Oncology Immuno Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Oncology Immuno Drug Revenue Market Share by Application (2021-2032) Figure 39. Global Oncology Immuno Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Oncology Immuno Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Oncology Immuno Drug Sales Market Share by Application (2021-2032) Figure 42. North America Oncology Immuno Drug Revenue Share by Type (2021-2032) Figure 43. North America Oncology Immuno Drug Sales Share by Type (2021-2032) Figure 44. North America Oncology Immuno Drug Revenue Share by Application (2021-2032) Figure 45. North America Oncology Immuno Drug Sales Share by Application (2021-2032) Figure 46. North America Oncology Immuno Drug Revenue Share by Country (2021-2032) Figure 47. North America Oncology Immuno Drug Sales Share by Country (2021-2032) Figure 48. Europe Oncology Immuno Drug Revenue Share by Type (2021-2032) Figure 49. Europe Oncology Immuno Drug Sales Share by Type (2021-2032) Figure 50. Europe Oncology Immuno Drug Revenue Share by Application (2021-2032) Figure 51. Europe Oncology Immuno Drug Sales Share by Application (2021-2032) Figure 52. Europe Oncology Immuno Drug Revenue Share by Country (2021-2032) Figure 53. Europe Oncology Immuno Drug Sales Share by Country (2021-2032) Figure 54. China Oncology Immuno Drug Revenue Share by Type (2021-2032) Figure 55. China Oncology Immuno Drug Sales Share by Type (2021-2032) Figure 56. China Oncology Immuno Drug Revenue Share by Application (2021-2032) Figure 57. China Oncology Immuno Drug Sales Share by Application (2021-2032) Figure 58. Asia Oncology Immuno Drug Revenue Share by Type (2021-2032) Figure 59. Asia Oncology Immuno Drug Sales Share by Type (2021-2032) Figure 60. Asia Oncology Immuno Drug Revenue Share by Application (2021-2032) Figure 61. Asia Oncology Immuno Drug Sales Share by Application (2021-2032) Figure 62. Asia Oncology Immuno Drug Revenue Share by Country (2021-2032) Figure 63. Asia Oncology Immuno Drug Sales Share by Country (2021-2032) Figure 64. SAMEA Oncology Immuno Drug Revenue Share by Type (2021-2032) Figure 65. SAMEA Oncology Immuno Drug Sales Share by Type (2021-2032) Figure 66. SAMEA Oncology Immuno Drug Revenue Share by Application (2021-2032) Figure 67. SAMEA Oncology Immuno Drug Sales Share by Application (2021-2032) Figure 68. SAMEA Oncology Immuno Drug Revenue Share by Country (2021-2032) Figure 69. SAMEA Oncology Immuno Drug Sales Share by Country (2021-2032) Figure 70. Oncology Immuno Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Oncology Immuno Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T Cell Therapy
  • Cancer Vaccines
  • Cytokine-Based Immunotherapy
  • Immune Checkpoint Inhibitors
  • Other
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Dendreon Pharmaceuticals
  • Gilead Sciences Inc.
  • Merck & Co
  • Sanofi S.A.
  • AstraZeneca
  • Roche AG
  • Merck KGaA
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oncology Immuno Drug Market by Type
  3. 1.2.1 Global Oncology Immuno Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CAR-T Cell Therapy
  5. 1.2.3 Cancer Vaccines
  6. 1.2.4 Cytokine-Based Immunotherapy
  7. 1.2.5 Immune Checkpoint Inhibitors
  8. 1.2.6 Other
  9. 1.3 Oncology Immuno Drug Market by Application
  10. 1.3.1 Global Oncology Immuno Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Drugstores
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Oncology Immuno Drug Market Dynamics
  1. 2.1 Oncology Immuno Drug Industry Trends
  2. 2.2 Oncology Immuno Drug Industry Drivers
  3. 2.3 Oncology Immuno Drug Industry Opportunities and Challenges
  4. 2.4 Oncology Immuno Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Oncology Immuno Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Oncology Immuno Drug Revenue by Region
  3. 3.2.1 Global Oncology Immuno Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oncology Immuno Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Oncology Immuno Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Oncology Immuno Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Oncology Immuno Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Oncology Immuno Drug Sales by Region
  9. 3.4.1 Global Oncology Immuno Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Oncology Immuno Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Oncology Immuno Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Oncology Immuno Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Oncology Immuno Drug Revenue by Manufacturers
  2. 4.1.1 Global Oncology Immuno Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Oncology Immuno Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Oncology Immuno Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oncology Immuno Drug Sales by Manufacturers
  6. 4.2.1 Global Oncology Immuno Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Oncology Immuno Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Oncology Immuno Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Oncology Immuno Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Oncology Immuno Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Oncology Immuno Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Oncology Immuno Drug Manufacturers, Product Type & Application
  13. 4.7 Global Oncology Immuno Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Oncology Immuno Drug Market CR5 and HHI
  16. 4.8.2 2025 Oncology Immuno Drug Tier 1, Tier 2, and Tier 3
5 Oncology Immuno Drug Market by Type
  1. 5.1 Global Oncology Immuno Drug Revenue by Type
  2. 5.1.1 Global Oncology Immuno Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Oncology Immuno Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Oncology Immuno Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Oncology Immuno Drug Sales by Type
  6. 5.2.1 Global Oncology Immuno Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oncology Immuno Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Oncology Immuno Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Oncology Immuno Drug Price by Type
6 Oncology Immuno Drug Market by Application
  1. 6.1 Global Oncology Immuno Drug Revenue by Application
  2. 6.1.1 Global Oncology Immuno Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Oncology Immuno Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Oncology Immuno Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Oncology Immuno Drug Sales by Application
  6. 6.2.1 Global Oncology Immuno Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Oncology Immuno Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Oncology Immuno Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Oncology Immuno Drug Price by Application
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 Dendreon Pharmaceuticals
  8. 7.2.1 Dendreon Pharmaceuticals Company Information
  9. 7.2.2 Dendreon Pharmaceuticals Business Overview
  10. 7.2.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio
  12. 7.2.5 Dendreon Pharmaceuticals Recent Developments
  13. 7.3 Gilead Sciences Inc.
  14. 7.3.1 Gilead Sciences Inc. Company Information
  15. 7.3.2 Gilead Sciences Inc. Business Overview
  16. 7.3.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio
  18. 7.3.5 Gilead Sciences Inc. Recent Developments
  19. 7.4 Merck & Co
  20. 7.4.1 Merck & Co Company Information
  21. 7.4.2 Merck & Co Business Overview
  22. 7.4.3 Merck & Co Oncology Immuno Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck & Co Oncology Immuno Drug Product Portfolio
  24. 7.4.5 Merck & Co Recent Developments
  25. 7.5 Sanofi S.A.
  26. 7.5.1 Sanofi S.A. Company Information
  27. 7.5.2 Sanofi S.A. Business Overview
  28. 7.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi S.A. Oncology Immuno Drug Product Portfolio
  30. 7.5.5 Sanofi S.A. Recent Developments
  31. 7.6 AstraZeneca
  32. 7.6.1 AstraZeneca Company Information
  33. 7.6.2 AstraZeneca Business Overview
  34. 7.6.3 AstraZeneca Oncology Immuno Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca Oncology Immuno Drug Product Portfolio
  36. 7.6.5 AstraZeneca Recent Developments
  37. 7.7 Roche AG
  38. 7.7.1 Roche AG Company Information
  39. 7.7.2 Roche AG Business Overview
  40. 7.7.3 Roche AG Oncology Immuno Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Roche AG Oncology Immuno Drug Product Portfolio
  42. 7.7.5 Roche AG Recent Developments
  43. 7.8 Merck KGaA
  44. 7.8.1 Merck KGaA Company Information
  45. 7.8.2 Merck KGaA Business Overview
  46. 7.8.3 Merck KGaA Oncology Immuno Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Merck KGaA Oncology Immuno Drug Product Portfolio
  48. 7.8.5 Merck KGaA Recent Developments
  49. 7.9 Novartis
  50. 7.9.1 Novartis Company Information
  51. 7.9.2 Novartis Business Overview
  52. 7.9.3 Novartis Oncology Immuno Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Novartis Oncology Immuno Drug Product Portfolio
  54. 7.9.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Oncology Immuno Drug Market Size by Type
  2. 8.1.1 North America Oncology Immuno Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Oncology Immuno Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Oncology Immuno Drug Price by Type (2021-2032)
  5. 8.2 North America Oncology Immuno Drug Market Size by Application
  6. 8.2.1 North America Oncology Immuno Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Oncology Immuno Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Oncology Immuno Drug Price by Application (2021-2032)
  9. 8.3 North America Oncology Immuno Drug Market Size by Country
  10. 8.3.1 North America Oncology Immuno Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Oncology Immuno Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Oncology Immuno Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Oncology Immuno Drug Market Size by Type
  2. 9.1.1 Europe Oncology Immuno Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Oncology Immuno Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Oncology Immuno Drug Price by Type (2021-2032)
  5. 9.2 Europe Oncology Immuno Drug Market Size by Application
  6. 9.2.1 Europe Oncology Immuno Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Oncology Immuno Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Oncology Immuno Drug Price by Application (2021-2032)
  9. 9.3 Europe Oncology Immuno Drug Market Size by Country
  10. 9.3.1 Europe Oncology Immuno Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Oncology Immuno Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Oncology Immuno Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Oncology Immuno Drug Market Size by Type
  2. 10.1.1 China Oncology Immuno Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Oncology Immuno Drug Sales by Type (2021-2032)
  4. 10.1.3 China Oncology Immuno Drug Price by Type (2021-2032)
  5. 10.2 China Oncology Immuno Drug Market Size by Application
  6. 10.2.1 China Oncology Immuno Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Oncology Immuno Drug Sales by Application (2021-2032)
  8. 10.2.3 China Oncology Immuno Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oncology Immuno Drug Market Size by Type
  2. 11.1.1 Asia Oncology Immuno Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Oncology Immuno Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Oncology Immuno Drug Price by Type (2021-2032)
  5. 11.2 Asia Oncology Immuno Drug Market Size by Application
  6. 11.2.1 Asia Oncology Immuno Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Oncology Immuno Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Oncology Immuno Drug Price by Application (2021-2032)
  9. 11.3 Asia Oncology Immuno Drug Market Size by Country
  10. 11.3.1 Asia Oncology Immuno Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Oncology Immuno Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Oncology Immuno Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oncology Immuno Drug Market Size by Type
  2. 12.1.1 SAMEA Oncology Immuno Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Oncology Immuno Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Oncology Immuno Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Oncology Immuno Drug Market Size by Application
  6. 12.2.1 SAMEA Oncology Immuno Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Oncology Immuno Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Oncology Immuno Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Oncology Immuno Drug Market Size by Country
  10. 12.3.1 SAMEA Oncology Immuno Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Oncology Immuno Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Oncology Immuno Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Oncology Immuno Drug Value Chain Analysis
  2. 13.1.1 Oncology Immuno Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Oncology Immuno Drug Production Mode & Process
  6. 13.2 Oncology Immuno Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Oncology Immuno Drug Distributors
  9. 13.2.3 Oncology Immuno Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst